Some potential problems are rational. Difficulties in purchasing kits and protective gear to supply chain issue during the epidemic point, which can also bring nuisance in double dose distribution of vaccine for the whole country.
Other potential concerns are more humane. Encouraging people to show up to get vaccinated not once, but twice can be a daunting task.
“There is no question that this is going to be the most complex, the largest vaccination program in human history, and it will take a level of effort, a level of sophistication that we have never tried before,” said Dr. Said Kelly Moore. , Professor of Health Policy at Wonderbilt University.
So far, the pace of Operation Operations, the federal government’s efforts to get the vaccine on the market, has given money to six pharmaceutical companies.
Two of those companies, Moderna and Pfizer, are now in Phase 3, large-scale clinical trials. In each trial, 30,000 volunteers received two doses, with Moderna keeping their shots at 28-day intervals and Pfizer at 21-day intervals.
AstraZeneca is expected to begin Phase 3 trials this month. Their Phase 1 and Phase 2 trials used two doses given 28 days apart.
Phase 3 trials are also yet to begin in Novavax but used two doses in previous tests.
Johnson’s and Johnson’s next phase In phase 3, some participants will take one dose and others two doses.
Sanofi has not announced whether his vaccine will be in one or two doses.
It is not surprising that the coronavirus vaccine will probably require two doses. Many vaccines require two doses, including childhood vaccine for chickenpox and hepatitis A and adult vaccine for shingles.
Some even need more – children get five doses of the DTAP vaccine, which protects against diphtheria, tetanus and pertussis.
That means the next coronavirus vaccine program will be difficult – but not impossible – to pull off.
“I’m confident we can do that, but that’s a big ask and we have to work with people to make it work,” Moore said.
Rational issues
First, creating 660 million doses for 330 million Americans is a daunting feat.
“We’re looking for a double shot. That’s double the amount,” said Nada Sanders, a professor of supply chain management at Northeastern University. “Doubling is a huge supply chain issue.”
It doesn’t just produce vaccines.
“You have to double everything in the supply chain,” Sanders said. “Syringe, can it be doubled? Can the vials be doubled? Can the stoppers be doubled? Can the needle be doubled? Everyone has to double, and then all of them have to get to different companies on time with that supply. Chain
Sanders says the U.S. He is concerned about the history of the Kovid-1ov epidemic, so there are rational problems in the market, including delays in testing, and difficulty in supplying health care workers with protective gear.
Just before the epidemic began, there was a shortage of shingles, a vaccine for shingles.
“We’re talking about such accuracy, and we couldn’t get the PPE right, so I’m concerned,” Sanders said. “There are a lot of vulnerabilities in this supply chain – a lot. If we don’t address this now, the chances of failure are much higher.”
Human problems
It seems that the majority of Americans will find it difficult to show up only once for a vaccine, let alone twice.
According to a CNN poll conducted this month, 40% of Americans say they will not get vaccinated, even if it is free and easy.
Even for people who want a vaccine, though, it’s a big deal to ask for it twice.
People have to remember to come a second time. They will have time to work – twice. They may have to wait in long lines – twice. And probably experience unpleasant side effects, such as fever – twice.
There are ways to overcome these barriers, such as mobile clinics, to get people vaccinated instead of the other way around.
D These. “These are the kinds of things I think we need to think about, so we can encourage people to come back and make it as easy as possible for them to follow the two-shot deal,” Nelson Michael said. , Director of the Center for Infectious Diseases Research at the Verter Reed Army Institute Research Research, who has been assigned to work with Operation Operation and Speed Speed.
Michael, who has also worked on the vaccine campaign before, said the challenges are real.
“I think if you leave the public health community they will find a way.” “But the task will be very difficult.”
.
